Global Cetirizine Hydrochloride Market is segmented By Application (Allergic Rhinitis, Allergic Conjunctivitis, Chronic Urticaria, Eczema, Others), By Dosage Form (Tablet, Syrups, Solution), By Distribution Channels (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Global Cetirizine Hydrochloride Market reached US$ 6,797.9 million in 2023 and is expected to reach US$ 8,882.5 million by 2031 growing with a CAGR of 3.4% during the forecast period 2024-2031.
Cetirizine hydrochloride is a second-generation antihistamine that works by selectively blocking the action of histamine, a chemical released by the body during an allergic reaction. Histamine binds to H1 receptors on target cells, triggering a cascade of events that leads to the typical symptoms of allergies such as sneezing, itchy and watery eyes, runny nose, and hives.
By binding to the H1 receptors, cetirizine prevents histamine from exerting its effects, thereby alleviating allergy symptoms. Compared to first-generation antihistamines, cetirizine has a higher affinity for the H1 receptor and is less likely to cross the blood-brain barrier, resulting in fewer central nervous system side effects like drowsiness.
The broad applicability of cetirizine for various allergic conditions, along with its favorable safety profile, has made it a widely preferred option among healthcare providers for patients spanning all age groups, from young children to the elderly.
Market Scope
Metrics |
Details |
CAGR |
3.4% |
Size Available for Years |
2022-2031 |
Forecast Period |
2024-2031 |
Data Availability |
Value (US$ Mn) |
Segments Covered |
Dosage Form, Age Group, Application, and Distribution Channel |
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
Largest Region |
North America |
Fastest Growing Region |
Asia-Pacific |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other Key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Increasing prevalence of allergic diseases
The demand for the global cetirizine hydrochloride market is driven by multiple factors. One of the key factors is the increasing prevalence of allergic diseases. The rise in allergic conditions, such as allergic rhinitis, eczema, and allergic conjunctivitis, is a primary driver for the cetirizine market.
Currently, over 150 million Europeans suffer from chronic allergic diseases. This number is expected to rise, with predictions indicating that by 2025, more than 50% of the EU population could be affected by allergies, including conditions like allergic rhinitis, asthma, and eczema. There is a growing awareness among the public regarding allergies and the available treatment options, which is leading to an increased demand for cetirizine. As more individuals become familiar with the symptoms of allergies, they are more inclined to seek effective medications to alleviate their discomfort.
Moreover, key players in the industry more focus on research & development, and a rising number of clinical trials are helping to propel this market growth. For instance, in January 2024, UCB announced the randomized Phase III Study aims to assess the efficacy and safety of Xyzal (levocetirizine) compared to Zyrtec (cetirizine) in subjects suffering from dermatitis. This type of study is crucial in clinical research as it provides robust data on how well these medications perform in treating dermatitis, which is often characterized by inflammation, redness, and itching of the skin.
Restraints
Factors such as side effects & adverse reactions associated with the drugs, and stringent regulatory requirements, are expected to hamper the market.
Market Segment Analysis
The global cetirizine hydrochloride market is segmented based on dosage form, age group, application, distribution channels, and region.
The tablets segment accounted for approximately 64.3% of the global cetirizine hydrochloride market share
The tablets segment is expected to hold the largest market share over the forecast period. Cetirizine hydrochloride tablets are essential in the global market as a reliable treatment for various allergic conditions, such as allergic rhinitis, chronic urticaria, and allergic conjunctivitis. The increasing prevalence of allergies and growing awareness of effective allergy management strategies are anticipated to sustain the demand for cetirizine tablets over the forecast period.
In addition, key players in the industry strategies such as partnerships and collaborations are helping to propel this market growth. For instance, in August 2023, the National Medical Products Administration (NMPA) granted Xinhua Pharmaceutical (Gaomi) Co., Ltd., a wholly-owned subsidiary of Xinhua Pharmaceutical, the Approval Letter of Supplementary Application for Cetirizine Hydrochloride Tablets. This approval signifies that the product has successfully passed the quality and efficacy consistency evaluation required for generic drugs.
Market Geographical Share
North America accounted for approximately 43.9% of the global cetirizine hydrochloride market share
North America region is expected to hold the largest market share over the forecast period owing to the rise in allergic disorders, such as allergic rhinitis, chronic urticaria, and allergic conjunctivitis, which is a major factor propelling the demand for cetirizine hydrochloride in this region.
Allergic rhinitis, commonly known as hay fever, is a prevalent condition that affects a significant portion of the global population, with prevalence estimates ranging from 10% to 30%. In the United States, a substantial percentage of adults and children have reported experiencing seasonal allergies in recent years. According to data from the CDC, approximately 25.7% of U.S. adults and 18.9% of children stated they suffered from seasonal allergies in 2021.
This high prevalence of allergic rhinitis in the U.S. population creates a significant demand for antihistamine medications like cetirizine, which are effective in alleviating common symptoms associated with this condition, such as sneezing, runny nose, and itchy eyes. Moreover, growing public awareness of allergies and the treatment options accessible has led to a heightened demand for cetirizine.
Additionally, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, and mergers & acquisitions are helping to propel this market growth in the region. For instance, in June 2022, Glenmark Pharmaceuticals Inc., USA, a fully owned subsidiary of Glenmark Pharmaceuticals Ltd., acquired the approved Abbreviated New Drug Applications (ANDAs) for several over-the-counter (OTC) drugs from Wockhardt Limited in the United States.
The acquired ANDAs include famotidine tablets USP, 10 mg and 20 mg (OTC) - used to treat and prevent ulcers in the stomach and intestine, cetirizine hydrochloride Tablets USP, 5 mg and 10 mg (OTC) - an antihistamine medication, and olopatadine hydrochloride ophthalmic solution USP, 0.1% (OTC) - indicated for allergic conjunctivitis and allergic rhinitis.
Market Segmentation
By Dosage Form
- Tablets
- Solutions
- Syrups
By Age Group
- Adult
- Pediatric
By Applications
- Allergic Rhinitis
- Allergic Conjunctivitis
- Chronic Urticaria
- Eczema
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- The rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Competitive Landscape
The major global players in the cetirizine hydrochloride market include Johnson & Johnson Services, Inc., GSK plc, UCB S.A., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Major Pharmaceuticals, Cipla, Dr. Reddys Laboratories Ltd., AdvaCare Pharma, and Aden Healthcare among others.
Key Developments
- In April 2023, Nicox SA announced that its exclusive partner in China, Ocumension Therapeutics, has submitted a New Drug Application (NDA) to obtain approval for the commercialization of Zerviate (cetirizine ophthalmic solution) at a concentration of 0.24%. This application is specifically for treating ocular itching associated with allergic conjunctivitis.
Why Purchase the Report?
- To visualize the global cetirizine hydrochloride market segmentation based on dosage form, age group, application, distribution channels, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of the cetirizine hydrochloride market with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The global cetirizine hydrochloride market report would provide approximately 70 tables, 63 figures, and 183 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies